MedPath

Better Contraceptive Choices: Immediate or Delayed Insertion of IUC After Second Trimester Abortion

Phase 4
Conditions
Pregnancy
Interventions
Procedure: Immediate insertion
Procedure: Interval insertion
Registration Number
NCT00877344
Lead Sponsor
University of British Columbia
Brief Summary

Hypothesis

Intrauterine contraception placed immediately after a second trimester abortion will result in fewer pregnancies than current standard practice of intended placement at 4 weeks post-abortion.

Study Design

Randomized Controlled Trial after their second trimester abortion comparing immediate with delayed insertion of IUC, and a non intervention control group choosing non-intrauterine contraception. Participants choosing an IUC will be randomly assigned to immediate or delayed insertion. The investigators primary outcome is pregnancy rate within one year.

Detailed Description

This Randomized Controlled Trial will be offered to women choosing to have a LNG-IUC or CuT380 after an abortion for gestational ages from 12 to 24 weeks. \[delete next insert\]"and a non intervention control group offered to all others having abortions at this gestational age". Participants choosing an LNG-IUC or CUT380 will be randomly assigned to immediate or interval insertion. In conjunction with follow up visits and questionnaires, the British Columbia Linked Health Database access will determine pregnancy rate within one year for the two intervention groups \[delete next insert\] and in relation to the various contraceptive choices made by the women not choosing intrauterine contraception. All women will complete surveys at 3, 6, 12, 24, 36, 48 and 72 months on their satisfaction with the contraceptive method chosen and on their satisfaction with study participation.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
474
Inclusion Criteria
  1. Have completed informed consent for an abortion at gestation between 12 weeks zero days and 23 weeks 6 days, and
  2. Choosing an IUC (either LNG-IUC or CuT380-IUC) for contraception post abortion, and
  3. Residents of British Columbia, registered with the Medical Services Plan health care system.
Exclusion Criteria
  1. Intention to move from BC within the next year
  2. Intention to conceive within the next year.
  3. Any of the following contraindications to use of a LNG-IUC or a CuT380-IUC
  4. Post Randomization Exclusion:

uterine perforation at the time of abortion

bleeding of more than 500 cc during abortion

any of the above exclusions detected at time of abortion

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Immediate insertionImmediate insertion of either a LNG-IUC or a Copper T380 IUD after 12-24 week abortion
2Interval insertionInterval insertion (two to four weeks post abortion) of either a LNG-IUC or a Copper T380 IUD after 12-24 abortion
Primary Outcome Measures
NameTimeMethod
Pregnancy rate at one year12 months

The one year pregnancy rate outcome will be determined using a pragmatic approximation based on the varying exactitude of imputations based on provincial Medical Service Plan billings related to abortions, miscarriages, still births and live births. Subsequent abortions performed within our study clinics for enrolled participants will be noted along with specific clinical information on pregnancy duration. For abortions performed elsewhere such as those for BC university students studying out of province, or those performed by individual physicians at rural or remote hospitals within BC, exact gestation may not be available. In the BC health administrative databases abortions are billed as under 7 weeks for medical abortions, and as under 14 weeks, 14 weeks to under 18 weeks, and 18 weeks and over for surgical abortions. Miscarriages by definition occur anytime under 20 weeks or are classed as still birth when over 20 weeks of gestation.

Secondary Outcome Measures
NameTimeMethod
Rates at one year for Expulsion, Continuation of use, Satisfaction with method, Adverse events.60 months

Secondary outcomes will be assessed initially at one year, then annually through the five year device effectiveness period.

Trial Locations

Locations (3)

Kelowna General Hospital Women's Services Clinic

🇨🇦

Kelowna, British Columbia, Canada

BC Women's Hospital

🇨🇦

Vancouver, British Columbia, Canada

Elizabeth Bagshaw Women's Clinic

🇨🇦

Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath